Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema.

The aim of this study was to investigate whether bronchoalveolar lavage (BAL) and serum levels of proinflammatory cytokines discriminate between different entities of patients with acute respiratory failure. BAL and circulating concentrations of interleukin-6 (IL-6), interleukin-8 (IL-8) and tumour necrosis factor-alpha (TNF-alpha) were measured in 74 mechanically-ventilated patients and 17 healthy controls. Patients were classified as cardiogenic pulmonary oedema (CPO), acute respiratory distress syndrome (ARDS), primary severe pneumonia (PN) and a combined group (PN+ARDS). In all patients with ARDS and/or PN, markedly elevated BAL levels of IL-6 and IL-8 were detected, which were significantly greater than levels in CPO and healthy controls. Absolute quantities and time-course of these cytokines did not differentiate between the absence and presence of lung infection, or different categories of PN. Similarly, circulating IL-6 levels were comparably elevated in patients with ARDS and/or PN, whereas circulating IL-8 concentrations were inconsistently increased. TNF-alpha was rarely detected in BAL samples, but increased serum concentrations were measured in ARDS and/or PN patients. Bronchoalveolar lavage levels of interleukin-6 and interleukin-8, but not tumour necrosis factor-alpha, and serum concentrations of interleukin-6 are consistently elevated in acute respiratory distress syndrome and/or severe pneumonia, discriminating these entities from cardiogenic pulmonary oedema. Alveolar and systemic cytokine profiles do not differentiate between acute respiratory distress syndrome in the absence of lung infection and states of severe primary or secondary pneumonia, which evidently present with comparable local and systemic inflammatory sequelae.

[1]  F. Stentz,et al.  Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. , 1995, Chest.

[2]  W. Seeger,et al.  Endotoxin "priming" potentiates lung vascular abnormalities in response to Escherichia coli hemolysin: an example of synergism between endo- and exotoxin , 1994, The Journal of experimental medicine.

[3]  I. Chaudry,et al.  Pentoxifylline attenuates oxygen-induced lung injury. , 1994, The Journal of surgical research.

[4]  W. Shoemaker,et al.  Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury , 1994, Critical care medicine.

[5]  J. Cavaillon,et al.  Circulating interleukin‐8 concentrations in patients with multiple organ failure of septic and nonseptic origin , 1994, Critical care medicine.

[6]  P. Montravers,et al.  High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome , 1993, Infection and immunity.

[7]  W. Seeger,et al.  Endotoxin primes perfused rabbit lungs for enhanced vasoconstrictor response to staphylococcal alpha-toxin. , 1993, The American review of respiratory disease.

[8]  M. Humbert,et al.  IN SITU PRODUCTION OF INTERLEUKIN‐6 WITHIN HUMAN LUNG ALLOGRAFTS DISPLAYING REJECTION OR CYTOMEGALOVIRUS PNEUMONIA , 1993, Transplantation.

[9]  R. Strieter,et al.  Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups , 1993, The Lancet.

[10]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[11]  M. Chiaranda,et al.  Levels of interleukin-8 in patients with adult respiratory distress syndrome. , 1993, The Journal of infectious diseases.

[12]  L. Bossaert,et al.  Interleukin 8 (IL-8) in the bronchoalveolar lavage fluid from patients with the adult respiratory distress syndrome (ARDS) and patients at risk for ARDS. , 1992, Cytokine.

[13]  P. Montravers,et al.  Subpopulation of hyperresponsive polymorphonuclear neutrophils in patients with adult respiratory distress syndrome. Role of cytokine production. , 1992, The American review of respiratory disease.

[14]  S. Garbisa,et al.  Spontaneous production of interleukin-6 by alveolar macrophages from human immunodeficiency virus type 1-infected patients. , 1992, The Journal of infectious diseases.

[15]  P. Parsons,et al.  Studies on the role of tumor necrosis factor in adult respiratory distress syndrome. , 1992, The American review of respiratory disease.

[16]  S. Peters,et al.  A multicenter registry of patients with acute respiratory distress syndrome. Physiology and outcome. , 1992, The American review of respiratory disease.

[17]  M. Matthay,et al.  Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. , 1992, The American review of respiratory disease.

[18]  C. Hack,et al.  Interleukin-8 in sepsis: relation to shock and inflammatory mediators , 1992, Infection and immunity.

[19]  R. Strieter,et al.  Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection , 1992, Infection and immunity.

[20]  S. Suter,et al.  High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. , 1992, The American review of respiratory disease.

[21]  M. Silverman,et al.  Increased levels of bronchoalveolar lavage fluid interleukin-6 in preterm ventilated infants after prolonged rupture of membranes. , 1992, The American review of respiratory disease.

[22]  B. Hazenberg,et al.  Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute‐phase proteins during the treatment of severe sepsis in humans , 1992, Critical care medicine.

[23]  A. Fowler,et al.  Tumor necrosis factor levels in serum and bronchoalveolar lavage fluid of patients with the adult respiratory distress syndrome. , 1991, The American review of respiratory disease.

[24]  L. Moldawer,et al.  IL-8 in septic shock, endotoxemia, and after IL-1 administration. , 1991, Journal of immunology.

[25]  J. Jenkins,et al.  Tumor necrosis factor. Alpha and beta subtypes appear in circulation during onset of sepsis-induced lung injury. , 1991, The American review of respiratory disease.

[26]  M. Schaller,et al.  Plasma levels of tumor necrosis factor in the adult respiratory distress syndrome. , 1991, The American review of respiratory disease.

[27]  J. Damme.  Interleukin-8 and related molecules , 1991 .

[28]  T. Standiford,et al.  Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. , 1991, Experimental lung research.

[29]  J. Kelley.  Cytokines of the lung. , 1992, The American review of respiratory disease.

[30]  R. Tompkins,et al.  Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. , 1990, The Journal of infectious diseases.

[31]  H. Büller,et al.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. , 1990, Blood.

[32]  L. G. Thijs,et al.  Increased plasma levels of interleukin-6 in sepsis [see comments] , 1989 .

[33]  M. Singer,et al.  TUMOUR NECROSIS FACTOR IN BRONCHOPULMONARY SECRETIONS OF PATIENTS WITH ADULT RESPIRATORY DISTRESS SYNDROME , 1989, The Lancet.

[34]  W. Buurman,et al.  Plasma tumor necrosis factor and mortality in critically ill septic patients. , 1989, Critical care medicine.

[35]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[36]  J. S. Solís Herruzo.  [Tumor necrosis factor-alpha (cachectin)]. , 1989, Revista clinica espanola.

[37]  L A Aarden,et al.  Increased plasma levels of interleukin-6 in sepsis. , 1989, Blood.

[38]  B. Beutler,et al.  The role of cachectin/TNF in endotoxic shock and cachexia. , 1988, Immunology today.

[39]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[40]  M. Rosenblum,et al.  Phase I study of recombinant tumor necrosis factor in cancer patients. , 1987, Cancer research.

[41]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[42]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[43]  W. Johanson,et al.  Incidence, site, and outcome of infections in patients with the adult respiratory distress syndrome. , 1986, The American review of respiratory disease.

[44]  R. Crystal,et al.  Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. , 1986, Journal of applied physiology.

[45]  Hyers Tm,et al.  Adult respiratory distress syndrome: causes, morbidity, and mortality. , 1986, Federation proceedings.

[46]  A. Fowler,et al.  Adult respiratory distress syndrome: causes, morbidity, and mortality. , 1986, Federation proceedings.

[47]  G. Campbell,et al.  The effect of bacterial superinfection on lung function after diffuse alveolar damage. , 1984, The American review of respiratory disease.

[48]  R. G. Fraser.  DIAGNOSIS OF DISEASES OF THE CHEST , 1978, The Ulster Medical Journal.